Glenmark Pharmaceuticals S A (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announced that it has successfully completed the phase I trial of GRC 15300, a first in class TRPV3 inhibitor for treatment of pain.

GRC 15300 is an inhibitor of the TRPV3 (Transient Receptor Potential cation channel, subfamily V, member 3). This is the first TRPV3 inhibitor which entered clinical trials. Glenmark has completed phase I dosing and analysis of the study data of GRC 15300 in the UK and the drug has been well tolerated with a good pharmacokinetic profile. Plans are in place to initiate clinical proof of concept studies in neuropathic pain. Sanofi has licensed the rights to all therapeutic indications.

Speaking on this development, Glenn Saldanha, chairman & MD, Glenmark Pharmaceuticals Ltd., said, “GRC 15300 is worldwide the first TRPV3 inhibitor which has successfully finished a phase I study. It is an exciting target and we are looking forward to continued development on the programme. Glenmark’s continued ability to bring novel first in class programmes into clinics demonstrates our growing capabilities to innovate in the drug discovery space.”

GPL is a research-driven, global, integrated pharmaceutical company in the discovery of new molecules, both NCEs (New Chemical Entity) and NBEs (New Biological Entity).